Company intelligence / Profile preview

COR Therapeutics

South San Francisco, California, United Statescortherapeutic.com ↗

Ownership: Private
Development stage: Other

Overview

COR Therapeutics developed cardiovascular drugs, most notably Integrelin (eptifibatide), a peptide-based antiplatelet agent targeting the glycoprotein IIb/IIIa receptor for acute coronary syndromes. The company also worked on small molecule inhibitors of coagulation factors such as factor Xa. Its lead product reached commercial stage before the company was acquired by Millennium Pharmaceuticals in 2002.

Therapeutic areas: Cardiovascular
Modalities: Small moleculePeptides (e.g., eptifibatide)
Industry: Biotech

Beyond the preview

Go deeper on COR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COR Therapeutics.

Explore the full profile